Search results for: antibody
#34118734 2021/05/27 To Up
Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic COVID-19 patients.Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pandemic. However, data concerning the epidemiological features, viral shedding, and antibody dynamics between asymptomatic SARS-CoV-2 carriers and COVID-19 patients remain controversial.
Yi Chen, Ping Li, Yibo Ding, Miao Liu, Leijie Liu, Bo Yi, Ting Wu, Hongjun Dong, Xuying Lao, Keqing Ding, Haibo Wang, Dongliang Zhang, Xiaojie Tan, Zhongfa Wang, Guozhang Xu, Guangwen Cao
2965 related Products with: Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic COVID-19 patients.200ug200ul200ug1,000 tests100ul100ug200ul100ug1000 tests100ul10 mg100ug
#34118732 2021/04/24 To Up
Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia.Estimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients.
Naif Khalaf Alharbi, Suliman Alghnam, Abdullah Algaissi, Hind Albalawi, Mohammed W Alenazi, Areeb M Albargawi, Abdullah G Alharbi, Abdulaziz Alhazmi, Ali Al Qarni, Ali Alfarhan, Hosam M Zowawi, Hind Alhatmi, Jahad Alghamdi, Fayhan Alroqi, Khalid Batarfi, Yaseen M Arabi, Anwar M Hashem, Mohammed Bosaeed, Omar Aldibasi100ug Lyophilized20ug50 mg2000 Units10 mg20mg2800200ul1mg20x50 ug
#34118585 2021/05/28 To Up
The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.Despite inclusion in neuromyelitis optica spectrum disorders (NMOSD), myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases are increasingly recognized as an independent disease entity. In this study, we conducted a systematic review and meta-analysis to comprehensively update the rate of occurrence of MOG-Ab in Aquaporin4 (AQP4)-antibody seronegative NMOSD.
Xindi Li, Chengyi Zhang, Dongmei Jia, Moli Fan, Ting Li, De-Cai Tian, Yaou Liu, Fu-Dong Shi
2744 related Products with: The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.4 Arrays/Slide4 Membranes/Box4 Membranes/Box4 Membranes/Box4 Arrays/Slide2 Pieces/Box4 Membranes/Box4 Membranes/Box4 Arrays/Slide4 Arrays/Slide4 Membranes/Box
#34118539 2021/06/05 To Up
Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters.C
Xiaoting Yu, Xu Zhang, Jingjing Xu, Pengyan Guo, Xiangmei Li, Hong Wang, Zhenlin Xu, Hongtao Lei, Xing Shen
2843 related Products with: Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters.2x 100ug100 μg2 Pieces/Box100 μg100 μg10 100 μg10 10 25 μg100 μg
No related Items
#34118456 2021/06/09 To Up
Letter to the editor: Serum anti-AÎ² antibodies in cerebral amyloid angiopathy.
Yannick Chantran, Jean Capron, Diana Doukhi, Johanna Felix, MÃ©lanie FÃ©roul, Florian Kruse, Thomas Chaigneau, Guillaume DorothÃ©e, Thibault Allou, Xavier Ayrignac, Zina Barrou, Thomas de Broucker, Corina Cret, Guillaume Turc, Roxane Peres, Anne Wacongne, Marie Sarazin, Dimitri Renard, Charlotte Cordonnier, Sonia Alamowitch, Pierre Aucouturier
1903 related Products with: Letter to the editor: Serum anti-AÎ² antibodies in cerebral amyloid angiopathy.100 100 μg100 μg100 μg1 mg100 μg100 200.00 ug100 μg100 μg
No related Items
#34118428 2021/06/09 To Up
Level of Maternal Respiratory Syncytial Virus (RSV) F Antibodies in Hospitalized Children and Correlates of Protection.RSV is a major cause of lower respiratory infections among children, where no vaccine is available. The stabilized form of the fusion (F) protein, pre-F, is a leading vaccine candidate targeting different populations, including pregnant women. This study aimed to determine the magnitude and nature of RSV-directed maternal antibodies (matAbs) in hospitalized children with RSV infection.
Sara A Taleb, Khalid Al-Ansari, Gheyath K Nasrallah, Mohamed A Elrayess, Asmaa A Al-Thani, Alexandrine Derrien-Colemyn, Tracy J Ruckwardt, Barney S Graham, Hadi M Yassine
1473 related Products with: Level of Maternal Respiratory Syncytial Virus (RSV) F Antibodies in Hospitalized Children and Correlates of Protection.100 100 100 100 μg1 mL100 1 mg2 Pieces/Box100.00 ug100 μg100 μg1 mL
#34118402 2021/06/09 To Up
Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults.Endemic human coronaviruses (hCoVs) are common causative agents of respiratory tract infections, affecting especially children. However, in the ongoing SARS-CoV-2 pandemic, children are the least affected age-group. The objective of this study was to investigate the magnitude of endemic hCoVs antibodies in Finnish children and adults, and pre-pandemic antibody cross-reactivity with SARS-CoV-2. Antibody levels against endemic hCoVs start to rise at a very early age, reaching to overall 100% seroprevalence. No difference in the antibody levels was detected for OC43 but the magnitude of 229E-specific antibodies was significantly higher in the sera of children. OC43 and 229E hCoV antibody levels of children correlated significantly with each other and with the level of cross-reactive SARS-CoV-2 antibodies, whereas these correlations completely lacked in adults. Although none of the sera showed SARS-CoV-2 neutralization, the higher overall hCoV cross-reactivity observed in children might, at least partially, contribute in controlling SARS-CoV-2 infection in this population.
Kirsi Tamminen, Marjo Salminen, Vesna Blazevic
1477 related Products with: Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults.200ug200ug0.1 mg200ul1 ml10 mg200ul1000 TESTS/0.65ml1,000 tests100ug1 mg100ug Lyophilized
#34118379 2021/06/09 To Up
B cells acquire a unique and differential transcriptomic profile during pregnancy.Pregnancy alters B cell development and function. B cell activation is initiated by antigens binding to the BCR leading to B cell survival, proliferation, antigen presentation and antibody production. We performed a genome-wide transcriptome profiling of splenic B cells from pregnant (P) and non-pregnant (NP) mice and identified 1136 genes exhibiting differential expression in B cells from P mice (625 up- and 511 down-regulated) compared to NP animals. In silico analysis showed that B cell activation through BCR seems to be lowered during pregnancy. RT-qPCR analysis confirmed these data. Additionally, B cells from pregnant women stimulated in vitro through BCR produced lower levels of inflammatory cytokines compared to non-pregnant women. Our results suggest that B cells acquire a state of hypo-responsiveness during gestation, probably as part of the maternal immune strategy for fetal tolerance but also open new avenues to understand why pregnant women are at highest risk for infections.
Natalin Valeff, Damian Oscar Muzzio, Franziska Matzner, Marcos Dibo, Janine Golchert, Georg Homuth, Martin C Abba, Marek Zygmunt, Federico Jensen
1983 related Products with: B cells acquire a unique and differential transcriptomic profile during pregnancy.100ul100ul50 mg100ul25 mg1000 TESTS/0.65ml96T100ul100ul100 extractions
#34118347 2021/06/09 To Up
Recent Advances in Potential Drug Therapies Combating COVID-19 and Related Coronaviruses-A Perspective.Coronaviruses (CoVs) are a large family of viruses responsible for the severe pathophysiological effects on human health. The most severe outbreak includes Severe Acute Respiratory Syndrome (SARS-CoV), Middle East Respiratory Syndrome (MERS-CoV) and Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 poses major challenges to clinical management because no specific FDA-approved therapy yet to be available. Thus, the existing therapies are being used for the treatment of COVID-19, which are under clinical trials and compassionate use, based on in vitro and in silico studies. In this review, we summarize the potential therapies utilizing small molecules, bioactive compounds, nucleoside and nucleotide analogs, peptides, antibodies, natural products, and synthetic compounds targeting the complex molecular signaling network involved in COVID-19. In this reviewï¼230 natural and chemically synthesized drug therapies are described with their recent advances in research and development being done in terms of their chemical, structural and functional properties. This review focuses on possible targets for viral cells, viral proteins, viral replication, and different molecular pathways for the discovery of novel viral- and host-based therapeutic targets against SARS-CoV-2.
Shivraj Hariram Nile, Arti Nile, Shivkumar Jalde, Guoyin Kai
2175 related Products with: Recent Advances in Potential Drug Therapies Combating COVID-19 and Related Coronaviruses-A Perspective.5 mg100 assays2 Pieces/Box100 assays100 assays100 assays2 Pieces/Box100 assays100 assays100 assays2 Pieces/Box100 assays
#34118338 2021/06/09 To Up
Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood-brain barrier permeability for drug delivery to the brain in a non-human primate.Claudin-5 (CLDN-5) is an essential component of the tight junction seal in the blood-brain barrier. Previously, we showed that CLDN-5 modulation in vitro via an anti-CLDN-5 monoclonal antibody (mAb) may be useful for increasing the permeability of the blood-brain barrier for drug delivery to the brain. Based on these findings, here we examined the safety and efficacy of the anti-CLDN-5 mAb in a non-human primate. Cynomolgus monkeys were intravenously administered the anti-CLDN-5 mAb followed by fluorescein dye (376â¯Da), and the concentrations of the dye in the cerebrospinal fluid was examined. When the mAb was administered at 3.0â¯mg/kg, the concentration of dye in the cerebrospinal fluid was increased, and no behavioral changes or changes in plasma biomarkers for inflammation or liver, kidney, or heart injury were observed. However, a monkey that received the mAb at 6â¯mg/kg experienced convulsions, and subsequent histopathological examination of this animal revealed vasodilation in the liver, lung, and kidney; hemorrhage in the lung; and edema in the brain. Together, our data indicate that CLDN-5 might be a potential target for enhancing drug delivery to the brain, but also that the therapeutic window of the anti-CLDN-5 mAb may be narrow for separating efficacy and toxicity.
Keisuke Tachibana, Yosuke Hashimoto, Keisuke Shirakura, Yoshiaki Okada, Ryuichi Hirayama, Yumi Iwashita, Itsuki Nishino, Yukio Ago, Hiroyuki Takeda, Hiroki Kuniyasu, Masuo Kondoh
2240 related Products with: Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood-brain barrier permeability for drug delivery to the brain in a non-human primate.50 UG50ug100ug100 μg100ug 100 UG25 µg100 ul50 ul100ug
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia